CN111110734A

CN111110734A - Traditional Chinese medicine composition for treating arteriosclerosis, dosage form and application

Info

Publication number: CN111110734A
Application number: CN202010062256.0A
Authority: CN
Inventors: 林金华
Original assignee: Individual
Current assignee: Individual
Priority date: 2020-01-19
Filing date: 2020-01-19
Publication date: 2020-05-08

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for treating arteriosclerosis, a preparation form and an application thereof, wherein the traditional Chinese medicine composition comprises, by weight, 5-20 parts of American ginseng, 5-20 parts of pseudo-ginseng, 8-17 parts of hawthorn, 7-18 parts of kudzuvine root, 6-15 parts of largehead atractylodes rhizome, 3-12 parts of Chinese thorowax root, 2-12 parts of red paeony root and 0.5-7 parts of szechuan lovage rhizome, and the preparation form is a clinically acceptable preparation form and is selected from at least one of tea, granules, powder, decoction and tablets. The traditional Chinese medicine composition is an effective medicine for softening blood vessels and treating arteriosclerosis, has definite compatibility of medicines, can stabilize normal blood pressure while reducing blood pressure, can be taken for a long time, and has small side effect.

Description

Traditional Chinese medicine composition for treating arteriosclerosis, dosage form and application

Technical Field

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating arteriosclerosis, a preparation form and application.

Background

Arteriosclerosis is an inflammatory lesion of an artery, and can thicken and harden the wall of an artery, lose elasticity and narrow a lumen. Arteriosclerosis is a vascular disease that occurs with the age of a human, and it usually occurs in adolescents, and becomes severe and ill in the middle-aged and elderly. Along with the improvement of living standard of people, the incidence rate of cardiovascular arteriosclerosis is gradually increased, and the cardiovascular arteriosclerosis is one of the main causes of death of the old. Atherosclerosis (AS) is the most common and important type of arteriosclerosis characterized by lipid-like deposits in the intima of the affected arteries, accumulation of complex carbohydrates, subsequent fibrous tissue proliferation and calcium deposits, and lesions in the media of the arteries. The disease mainly involves large and medium-sized muscle elasticity type arteries, is mainly caused by the major causes of myocardial infarction and cerebral infarction, and often causes serious consequences such as lumen occlusion or vessel wall rupture bleeding and the like due to the fact that the major causes of the artery, the artery and the artery are aorta, coronary artery and cerebral artery. It affects the large and medium arteries and can cause considerable consequences. When coronary atherosclerosis occurs, myocardial blood supply is insufficient, and angina pectoris and myocardial infarction are caused; cerebral arteriosclerosis can cause cerebral blood supply insufficiency, dizziness and headache. In the later period of cerebral atrophy, there may be mental distortion, dementia, etc., thrombosis in cerebral artery or apoplexy caused by small aneurysm rupture bleeding due to atherosclerosis, which may cause serious consequences such as consciousness loss, hemiplegia, aphasia, etc.; renal arteriosclerosis can cause refractory hypertension; intestinal arteriosclerosis can cause dyspepsia, constipation, and diarrhea; lower extremity atherosclerosis can cause intermittent claudication, and in severe cases, ischemic necrosis of the extremities occurs.

In recent years, with the improvement of living standard and the aging of population structure, the incidence and death rate of the disease rapidly increase, and the incidence age tends to be younger. It is reported that about 110 million people die of this disease every year in our country. Therefore, the development of drugs for treating the disease is becoming a hot point of research. In recent years, many researchers of traditional Chinese medicine have focused on the use of Chinese medicinal compositions to treat arteriosclerosis. Although a plurality of prescriptions are clinically used for relieving or treating the arteriosclerosis diseases, the wide popularization and application is not available at present.

Disclosure of Invention

The invention aims to provide a traditional Chinese medicine composition for treating arteriosclerosis, which has definite compatibility of medicines, can reduce blood pressure, stabilize normal blood pressure, can be taken for a long time and has small side effect.

The invention also aims to provide a dosage form of the traditional Chinese medicine composition for treating arteriosclerosis.

The invention also aims to provide application of the traditional Chinese medicine composition for treating arteriosclerosis.

The invention adopts the following technical scheme that,

a Chinese medicinal composition for treating arteriosclerosis comprises, by weight, 5-20 parts of American ginseng, 5-20 parts of pseudo-ginseng, 8-17 parts of hawthorn, 7-18 parts of kudzu vine root, 6-15 parts of bighead atractylodes rhizome, 3-12 parts of radix bupleuri, 2-12 parts of red peony root and 0.5-7 parts of ligusticum wallichii.

Preferably, the traditional Chinese medicine composition is composed of 8-15 parts of American ginseng, 10-15 parts of pseudo-ginseng, 10-15 parts of hawthorn, 10-15 parts of kudzuvine root, 10-12 parts of largehead atractylodes rhizome, 5-10 parts of Chinese thorowax root, 5-10 parts of red paeony root and 1-5 parts of szechuan lovage rhizome.

More preferably, the traditional Chinese medicine composition comprises the following raw materials of 10-13 parts of American ginseng, 10-14 parts of pseudo-ginseng, 11-13 parts of hawthorn, 12-14 parts of kudzu root, 10-12 parts of bighead atractylodes rhizome, 6-9 parts of radix bupleuri, 6-9 parts of red paeony root and 2-4 parts of ligusticum wallichii.

Further preferably, the traditional Chinese medicine composition is composed of 13 parts of American ginseng, 14 parts of pseudo-ginseng, 13 parts of hawthorn, 14 parts of kudzuvine root, 10 parts of largehead atractylodes rhizome, 9 parts of Chinese thorowax root, 9 parts of red paeony root and 2 parts of szechuan lovage rhizome.

A dosage form of the traditional Chinese medicine composition according to any one of the above embodiments, wherein the dosage form is a clinically acceptable dosage form selected from at least one of a tea, a granule, a powder, a decoction and a tablet.

Use of a Chinese medicinal composition of any one of the embodiments above in the treatment of arteriosclerosis.

The traditional Chinese medicine composition comprises the following raw materials in part by weight:

american ginseng: cool in nature, sweet and slightly bitter in taste; it has effects in regulating blood pressure, lowering temporary or permanent blood pressure, lowering blood coagulability, inhibiting platelet aggregation, resisting atherosclerosis, and promoting erythrocyte growth.

Pseudo-ginseng: warm in nature, sweet and slightly bitter in taste; it enters liver and stomach meridians. The compendium of materia medica records that the bleeding can be stopped by stopping bleeding, dissipating blood and relieving pain, incised wound, traumatic injuries, crutch sores and ceaseless bleeding, and the blood can be stopped by chewing the medicine or mixing the medicine with the medicine. It is also indicated for hematemesis, epistaxis, bloody dysentery, metrorrhagia, menorrhagia, postpartum persistent blood, blood-moving pain, red eye, carbuncle and swelling, and snake bite.

The hawthorn is sour and sweet and is slightly warm; enter spleen, stomach and liver meridians. Ning Yuan food and literature and materia Medica: to resolve blood clots, remove qi clots and activate blood.

Kudzu root: sweet and pungent in flavor, cool in nature, entering lung and stomach meridians; the kudzu root has certain functions of relaxing blood vessels and reducing blood pressure; puerarin has obvious curative effect on headache, dizziness, tinnitus and other symptoms caused by blood pressure.

White atractylodes rhizome: bitter and sweet taste, warm nature; it enters spleen and stomach meridians. The main functions are strengthening spleen and replenishing qi, eliminating dampness and promoting diuresis, and arresting sweating.

Bupleurum root: bitter taste, neutral nature, meridian tropism, entering liver and gallbladder meridians; harmonize exterior and interior, soothe liver, relieve depression, raise yang and lift sinking.

Red peony root: bitter taste and slightly cold nature; it enters liver meridian. It is commonly indicated for heat entering nutrient-blood, warm toxicity and macula, hematemesis and epistaxis, conjunctival congestion and swelling pain, liver depression and hypochondriac pain, amenorrhea and dysmenorrhea, addictions and abdominal pain, traumatic injury, carbuncle, swelling and sore and ulcer.

Ligusticum wallichii: pungent in flavor and warm in nature, entering liver and gallbladder meridians. Move qi and relieve depression, dry dampness by Fangfeng, activate blood and alleviate pain; it is indicated for wind-cold headache, dizziness, hypochondriac pain, abdominal pain, cold arthralgia, spasm of tendons and muscles.

The invention has the beneficial effects that: the traditional Chinese medicine composition is an effective medicine for softening blood vessels and treating arteriosclerosis; the invention is safe, nontoxic, cheap and practical. All the raw material components of the traditional Chinese medicine composition belong to a list of traditional Chinese medicines published by the national ministry of health, which are both foods and medicines, are safe and nontoxic, and are suitable for long-term administration; after the traditional Chinese medicine composition is taken, the blood pressure can be effectively reduced, and the traditional Chinese medicine composition is safe and has no toxic or side effect.

Traditional Chinese medicine considers that the pathogenesis of atherosclerosis is divided into deficiency of origin and excess of origin, wherein the deficiency of origin is mainly qi deficiency and yin deficiency, the excess of origin is marked by blood stasis, phlegm turbidity, congealing cold and qi stagnation, and the pathogenesis of blood stasis runs through the whole process of the onset of carotid atherosclerosis. The invention mainly takes the traditional Chinese medicine raw materials for softening blood vessels and promoting blood circulation to remove blood stasis as main materials, and has clear compatibility. The compatibility principle of the invention is as follows: the American ginseng can regulate blood pressure, dilate blood vessels, effectively reduce temporary and persistent blood pressure, reduce blood coagulability, inhibit platelet aggregation, resist atherosclerosis, promote the growth of red blood cells and increase hemoglobin after long-term administration; the Panax notoginsenosides in Notoginseng radix have effects of promoting blood circulation, dilating blood vessel, increasing blood flow of coronary artery and cerebral vessels, and resisting blood platelet aggregation; lowering blood viscosity, inhibiting atherosclerosis, dissolving and inhibiting thrombosis, improving blood circulation, and improving myocardial and cerebral ischemia; meanwhile, the composition can also reduce arterial pressure, slightly reduce heart rate, enhance myocardial contractility and relieve cardiac burden, thereby obviously reducing myocardial oxygen consumption and playing a role in resisting arrhythmia; the hawthorn flavone which is the main component in hawthorn can obviously reduce the concentration of serum total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B of experimental hyperlipidemic animals, obviously increase the concentration of high-density lipoprotein-cholesterol and apolipoprotein, but has little influence on triglyceride; the hawthorn blood fat reducing effect is that the liver is promoted to take the effect of reducing blood fat by inhibiting the synthesis of liver cholesterol; the hawthorn flavone can also reduce the risk of atherosclerosis, and has the function of preventing the development of the atherosclerosis. The ligusticum wallichii, the rhizoma atractylodis macrocephalae and the radix bupleuri are ministerial drugs, and the radix puerariae has certain functions of relaxing blood vessels and reducing blood pressure; the white atractylodes rhizome has the vasodilating effect, and researches show that the white atractylodes rhizome has obvious inhibition effect on platelet aggregation and has the effect on the cardiovascular system: bupleuri radix has effects of dilating blood vessel and relieving blood vessel dyskinesia. The prescription adopts the combination of the ligusticum wallichii, the rhizoma atractylodis macrocephalae and the radix bupleuri as well as the drug effect of monarch drug, so as to exert the optimal effects of softening blood vessels and inhibiting the development of arteriosclerosis of the prescription. The red peony root and the rhizoma ligustici wallichii are used as adjuvant drugs, because of obstruction of blood vessels, stasis of heart blood and unfavorable blood circulation, atherosclerosis is easy to activate, and the red peony root has the function of removing blood stasis through a hose; the main effects of the ligusticum wallichii are promoting blood circulation to remove blood stasis, promoting qi circulation and relieving pain; the two materials are used as adjuvant, monarch and minister materials to soften blood vessel and achieve the purpose of promoting blood circulation and removing blood stasis.

Detailed Description

The following description of the embodiments of the present invention is provided by way of specific examples, and other advantages and effects of the present invention will be readily apparent to those skilled in the art from the disclosure herein.

It should be understood that the terms "upper", "inner", "outer", "bottom", "one" and "middle" used in the present specification are for convenience of description, and are not intended to limit the scope of the present invention, and that changes and modifications in the relative relationship may be made without substantial change in the technical content and the scope of the present invention.

Example 1

The formula of the traditional Chinese medicine composition 1 is as follows: 13 parts of American ginseng, 14 parts of pseudo-ginseng, 13 parts of hawthorn, 14 parts of kudzuvine root, 10 parts of largehead atractylodes rhizome, 9 parts of Chinese thorowax root, 9 parts of red paeony root and 2 parts of szechuan lovage rhizome.

Mixing the raw materials, adding 420 parts by weight of water, decocting for 40min, filtering to obtain a first filtrate, filtering to obtain a solid, adding 420 parts by weight of water, decocting for 40min, filtering to obtain a second filtrate, filtering to obtain a solid, adding 420 parts by weight of water, decocting for 40min, and filtering to obtain a third filtrate; mixing the first, second and fourth filtrates, concentrating to 170 weight parts, and making into medicated tea.

Example 2

The formula of the traditional Chinese medicine composition 2 is as follows: 20 parts of American ginseng, 5 parts of pseudo-ginseng, 8 parts of hawthorn, 18 parts of kudzuvine root, 6 parts of largehead atractylodes rhizome, 3 parts of Chinese thorowax root, 6 parts of red paeony root and 0.5 part of szechuan lovage rhizome. The Chinese medicinal composition 2 can be made into tea.

Example 3

The formula of the traditional Chinese medicine composition 3 is as follows: 5 parts of American ginseng, 15 parts of pseudo-ginseng, 10 parts of hawthorn, 15 parts of kudzuvine root, 12 parts of largehead atractylodes rhizome, 12 parts of Chinese thorowax root, 5 parts of red paeony root and 5 parts of szechuan lovage rhizome. The Chinese medicinal composition 3 is prepared into decoction.

Example 4

The formula of the traditional Chinese medicine composition 4 is as follows: 10 parts of American ginseng, 20 parts of pseudo-ginseng, 11 parts of hawthorn, 7 parts of kudzuvine root, 15 parts of largehead atractylodes rhizome, 6 parts of Chinese thorowax root, 12 parts of red paeony root and 7 parts of szechuan lovage rhizome. The Chinese medicinal composition 4 is prepared into granules.

Example 5

The formula of the traditional Chinese medicine composition 5 is as follows: 8 parts of American ginseng, 10 parts of pseudo-ginseng, 17 parts of hawthorn, 10 parts of kudzu root, 12 parts of bighead atractylodes rhizome, 5 parts of radix bupleuri, 10 parts of red paeony root and 4 parts of ligusticum wallichii. The Chinese medicinal composition 5 is in the form of powder.

Arteriosclerosis testing

Test animals: selecting 50 rats purchased from the experimental animal center of Hubei Chinese medicine university, wherein the rats are male at SPF level and the weight of the rats is 200-250 g; the room temperature is 25 +/-2 ℃, and the food and the water can be freely taken.

The experimental method and results are that after the rats are adaptively raised for one week, the rats are randomly divided into a normal group, a model group and a low-dose, medium-dose and high-dose tea preparation group (hereinafter referred to as a low-dose group, a medium-dose group and a high-dose group) for treating arteriosclerosis, wherein 10 normal control groups are fed with basic feed, 40 model groups are manufactured, the model group and each administration group are prepared into a rat arteriosclerosis model by adopting a method of injecting vitamin D360 ten thousand units per kg into abdominal cavity once, and simultaneously, the model group and each administration group are fed with high-fat feed and 10mL/kg fat emulsion (the fat emulsion is self-prepared by injecting cholesterol 25g, sodium cholate 5g, propylthiouracil 2.5g and lard 75g) into each 500mL fat emulsion, the low-dose group, the medium-dose group and the high-dose group are respectively injected with 10 mg/(kg. D), 25 mg. D) and 50 mg/(kg. D) of the traditional Chinese medicine composition of the example 1 into each day, the normal group and the model group are injected with water 1 day, distilled for 8 days continuously, the same amount, the eye administration is performed after the day, the injection is performed, the rat is subjected to the injection of the arterial blood vessel change of artery, the rat is measured by adopting a conventional method, the rat subcutaneous injection.

Table 1 effect of the test group on the hyperlipidemic lipid profile (in mmol/L) of the dietetic rats.

Group of	TC	TG	LDL-C	HDL-C
					Low dose group	1.58±0.32**	1.19±0.21**	0.80±0.23**	2.11±0.44**
Middle dose group	1.53±0.28**	1.15±0.22**	0.74±0.18**	2.23±0.52**
					High dose group	1.49±0.30**	1.11±0.19**	0.72±0.19**	2.49±0.48**
Normal group	1.18±0.22**	0.94±0.16**	0.63±0.22**	1.44±0.46**
					Model set	2.59±0.27	1.94±0.32	1.32±0.32	1.58±0.32

Note: p < 0.01 compared to model group.

Table 1 shows that the traditional Chinese medicine composition for treating arteriosclerosis has a remarkable regulation effect on abnormal lipid metabolism of an arteriosclerosis model rat, can obviously reduce the levels of cholesterol and low-density lipoprotein of the model rat, improves the ratio of high-density lipoprotein to low-density lipoprotein, and can inhibit thickening of a tunica media in the arterial wall of the model rat.

TABLE 2 test group Effect (P mol/L) on experimental rat blood TNF α, IL-1, IL-6, IL-10 and NF-kB

Group of	TNFα	IL-1	IL-6	IL-10	NF-kB
						Low dose group	1.63±0.27**	1.79±0.28**	1.80±0.33**	1.61±0.34**	1.27±0.21**
Middle dose group	1.51±0.24**	1.43±0.21**	1.74±0.14**	1.53±0.31**	1.43±0.44**
						High dose group	1.23±0.33**	1.38±0.19**	1.66±0.16**	1.49±0.28**	1.52±0.48**
Normal group	1.10±0.12**	1.36±0.26**	1.23±0.26**	1.77±0.36**	1.18±0.13**
						Model set	2.59±0.30	2.34±0.32	2.82±0.35	1.12±0.32	2.55±0.32

Note: p < 0.01 compared to model group.

The concentrations of TNF α, IL-1, IL-6 and NF-kB of rats in the model group are obviously improved, and the concentration of IL-10 is obviously reduced, and the high, medium and low doses of the invention can obviously reduce the concentrations of inflammatory factors TNF α, IL-1, IL-6 and NF-kB, improve the concentration of anti-inflammatory factors IL-10 and inhibit the over-expression of artery NF-KB.

Claims

1. A traditional Chinese medicine composition for treating arteriosclerosis is characterized by comprising, by weight, 5-20 parts of American ginseng, 5-20 parts of pseudo-ginseng, 8-17 parts of hawthorn, 7-18 parts of kudzu vine root, 6-15 parts of bighead atractylodes rhizome, 3-12 parts of radix bupleuri, 2-12 parts of red paeony root and 0.5-7 parts of ligusticum wallichii.

2. The traditional Chinese medicine composition as claimed in claim 1, which is prepared from 8-15 parts of American ginseng, 10-15 parts of pseudo-ginseng, 10-15 parts of hawthorn, 10-15 parts of kudzu root, 10-12 parts of bighead atractylodes rhizome, 5-10 parts of radix bupleuri, 5-10 parts of red peony root and 1-5 parts of ligusticum wallichii.

3. The traditional Chinese medicine composition as claimed in claim 2, which is prepared from 10-13 parts of American ginseng, 10-14 parts of pseudo-ginseng, 11-13 parts of hawthorn, 12-14 parts of kudzu root, 10-12 parts of bighead atractylodes rhizome, 6-9 parts of radix bupleuri, 6-9 parts of red peony root and 2-4 parts of ligusticum wallichii.

4. The traditional Chinese medicine composition of claim 3, which is prepared from 13 parts of American ginseng, 14 parts of pseudo-ginseng, 13 parts of hawthorn, 14 parts of kudzu root, 10 parts of bighead atractylodes rhizome, 9 parts of radix bupleuri, 9 parts of red peony root and 2 parts of ligusticum wallichii.

5. A dosage form of the Chinese medicinal composition of any one of claims 1 to 4, which is a clinically acceptable dosage form selected from at least one of a tea, a granule, a powder, a decoction and a tablet.

6. Use of a Chinese medicinal composition according to any one of claims 1 to 4 for the treatment of arteriosclerosis.